Our discovery suggests that the combination of EGFR kinase inhibitor with T-DM1 may be a promising novel therapeutic strategy to overcome primary T-DM1 resistance and warrants further pre-clinical and clinical investigation for the treatment of HER2-positive breast cancers. Here, ERBB2 is linked to breast cancer.